OTC Tip Reporter Announces Market News From Aikido Pharma Who Secured Early Interest in Next Generation Radiotherapy with Convergent Therapeutics, Inc.

Companies that trade on the NASDAQ or NYSE that are looking to remain qualified and increase visibility and exposure on the markets rely on OTC Tip Reporter. If your company is on the verge of being delisted from NASDAQ or the New York Stock Exchange (NYSE), OTC Tip Reporter can help you remain qualified. OTC Tip Reporter has been helping companies for years get their story out to investors and current shareholders that can assist these companies in remaining qualified on both NASDAQ and or the New York Stock Exchange (NYSE).  

Today, AIkido Pharma Inc. (Nasdaq: AIKI) announced that the Company executed a Two Million Dollar Convertible Promissory Note Purchase Agreement with Convergent Therapeutics, Inc., securing an early investment in Convergent. Convergent has exclusive rights to technology related to next generation radiopharmaceutical therapy for prostate cancer that is covered by multiple issued U.S. and foreign patents.

Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy ("PRRT") that targets the prostate-specific membrane antigen ("PSMA") present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

OTC Tip Reporter offers investor relations media packages to improve exposure to potential investors and shareholders. If you are a NASDAQ or NYSE trading company looking to start your marketing campaign with us, get in touch with OTC Tip Reporter at 800-850-9305.